Russia has highlighted the publication of a scientific article on the results of Phase I/II clinical trials on its coronavirus vaccine, Sputnik V.
The Lancet http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext has included the results of the trial, carried out in primates, Syrian hamsters and transgenic mice, with the data showing 100% protective efficacy of the vaccine.
Russia approved the vaccine despite the lack of Phase III data offering proof of the product’s safety or efficacy.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze